Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Rating of "Buy" by Analysts

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) have earned an average recommendation of "Buy" from the twelve analysts that are presently covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued a report on the stock in the last year is $107.36.

VRNA has been the topic of several research reports. Cowen assumed coverage on Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They set a "buy" rating on the stock. Wolfe Research assumed coverage on shares of Verona Pharma PLC American Depositary Share in a report on Tuesday. They set an "outperform" rating and a $170.00 target price for the company. Roth Capital reiterated a "buy" rating and set a $116.00 target price (up from $92.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, June 18th. Piper Sandler set a $160.00 target price on shares of Verona Pharma PLC American Depositary Share and gave the company an "overweight" rating in a report on Monday, June 23rd. Finally, Wells Fargo & Company lifted their target price on shares of Verona Pharma PLC American Depositary Share from $107.00 to $138.00 and gave the company an "overweight" rating in a report on Friday, June 20th.

Verona Pharma PLC American Depositary Share Stock Performance

Verona Pharma PLC American Depositary Share stock opened at $91.18 on Friday. The stock's 50 day simple moving average is $81.23 and its two-hundred day simple moving average is $65.74. The company has a debt-to-equity ratio of 1.07, a quick ratio of 8.73 and a current ratio of 8.86. The stock has a market cap of $7.76 billion, a price-to-earnings ratio of -45.59 and a beta of 0.24. Verona Pharma PLC American Depositary Share has a fifty-two week low of $15.56 and a fifty-two week high of $99.01.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million. As a group, analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel Andrew Fisher sold 80,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $11.53, for a total value of $922,400.00. Following the completion of the transaction, the general counsel directly owned 359,999 shares in the company, valued at $4,150,788.47. The trade was a 18.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark W. Hahn sold 400,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the completion of the transaction, the chief financial officer owned 12,278,992 shares of the company's stock, valued at approximately $139,980,508.80. The trade was a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,965,800 shares of company stock valued at $20,056,881 in the last quarter. Insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

Hedge funds have recently added to or reduced their stakes in the company. NBC Securities Inc. purchased a new position in Verona Pharma PLC American Depositary Share in the 1st quarter worth approximately $34,000. Geneos Wealth Management Inc. raised its stake in Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after buying an additional 193 shares during the last quarter. Vermillion Wealth Management Inc. purchased a new stake in Verona Pharma PLC American Depositary Share during the 4th quarter valued at $46,000. Acadian Asset Management LLC purchased a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter valued at $48,000. Finally, NewEdge Advisors LLC purchased a new stake in Verona Pharma PLC American Depositary Share during the 1st quarter valued at $58,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.